Actavis plant addition to create 220 jobs; Strides CEO sees growth in biologics after Agila deal;

@FiercePharma: Interesting look at Big Pharma's new-drug sales, a.k.a Freshness Index, from Forbes columnist Bernard Munos. Report | Follow @FiercePharma

@EricPFierce: Actavis getting nearly $3 million from taxpayers to expand a plant in Florida. Story | Follow @EricPFierce

> Actavis plans to invest $40.5 million into its plant in Davie, FL, in an expansion expected to create about 220 new jobs. Report

> Strides Arcolab CEO Arun Kumar figures the Indian company can beef up its biologics business and pharma sales to quickly replace revenues from its to-be-sold injectables unit Agila Specialties. Report

> Indian generics makers Lupin and Aurobindo Pharma won FDA approval for their versions of Diovan HCT, a combination blood-pressure pill made by Novartis ($NVS). Report

> The FDA approved Cangene's Botulism Antitoxin Heptavalent, the first antibody to combat all types of toxins known to cause botulism. Report

> China's Sinopharm says its 2012 profits are up 26% from 2011, at 1.97 billion yuan ($317 million). Report

> Indian pharmaceutical exports to Nigeria rose to $307 million for the most recent fiscal year, an increase of 35% over the previous year. Report

Medical Device News

 @FierceMedDev: Cornell: Metal stents work well as blocked bile duct treatment. Item | Follow @FierceMedDev

 @MarkHFierce: Third Rock is rolling out a new $516M VC fund, for device, Dx and biotech companies. Target: early-stage companies. Release | Follow @MarkHFierce

 @DamianFierce: Abbott is warning overseas surgeons about a safety issue with MitraClip, all as it seeks FDA approval. Report | Follow @DamianFierce

> Ohio company pulls in $9M Series B for laparoscopic visual shield. Story

> Argon puts $362.5M on Angiotech's interventionals biz. Article

> Prostate cancer patients driving penile implant boom. Report

Biotech News

 @FierceBiotech: More on CRO shutdown from FierceCRO.com: Former Cetero shutters ops, leaving sponsors, patients locked out. Story | Follow @FierceBiotech

@JohnCFierce: Third Rock Ventures adds $516M fund to back new portfolio of biotechs. News | Follow @JohnCFierce

@RyanMFierce: Astellas Pharma taps supercomputer for IT-driven drug discovery. More | Follow @RyanMFierce

> Versant adds $7.5M to upstart biotech's A round. Story

> Strike two: FDA hands United Therapeutics another rejection on oral Remodulin. Article

> Novartis snags FDA approval for antibiotic in CF patients. Story

CRO News

> Bayer deepens Cambodian presence with DKSH partnership. More

> Sanofi beefs up CMO game with Transgene deal. Item

> Dr. Reddy's wins $22.5M from CRO Nordion. News

> Duke's in-house CRO snags trial deal for RNAi drug. Article

> ShangPharma wins investor vote for go-private plan. Story

Biotech IT News

> BlackBerry founder bets on quantum tech in life sciences. Item

> NextDocs and Microsoft pushing clinical trials to the cloud. Story

> AstraZeneca IT chief talks up Big Data amid R&D turmoil. Report

> Biotech data merges onto UC San Diego's Big Data 'freeway.' Article

> Merck slashes data-management costs with China site. More

And Finally... The American Academy of Neurology said about 20% of surveyed members missed major FDA safety warnings on antiepileptic medicines. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.